GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Volumn 22, Issue 3, 2016, Pages 315-322

  Argento, Nicholas B ^a   Nakamura, Katherine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD GLUCOSE MONITORING; CASE CONTROL STUDY; CHILD; DEVICES; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CANAGLIFLOZIN; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2; YOUNG ADULT;

EID: 84982890345     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP151016.OR     Document Type: Article

References (0)